Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent Covering Methods For Treating TBI and Preventing Nerve Cell Death With Buntanetap
U.S. Patent No. 12,042,482 specifically addresses traumatic brain injury (“TBI”) treatment with buntanetap, enhancing Annovis Bio’s portfolio that includes various patents and applications for using buntanetap in treating both acute and chronic neurodegenerative diseases and mental illnesses Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43 TBI is one of the major causes of death and disability in the US with annual death rate exceeding 70,000 Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced the issuance of a U.S. patent for treating traumatic brain injury (“TBI”) with…